Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

MISSIONPHARMA GROUP ApS - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.6%   Bankruptcy risk   0.5% 1.3% 2.4% 2.5% 0.4% 0.5% 6.9% 7.0%   Credit score (0-100)   99 81 65 62 100 99 34 35   Credit rating   AA A BBB BBB AAA AAA BBB BBB   Credit limit (mDKK)   38.9 3.3 0.0 0.0 39.4 47.5 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Net sales   692 757 780 727 682 924 924 924   Gross profit   152 27.8 99.3 182 134 229 0.0 0.0   EBITDA   94.1 12.3 99.3 182 77.9 164 0.0 0.0   EBIT   82.9 9.4 99.3 182 69.0 160 0.0 0.0   Pre-tax profit (PTP)   87.9 31.6 17.0 78.1 69.3 154.4 0.0 0.0   Net earnings   70.1 32.9 17.0 78.1 52.3 119.3 0.0 0.0   Pre-tax profit without non-rec. items   87.9 3.4 99.3 182 69.3 154 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Tangible assets total   32.7 34.6 0.0 0.0 46.2 48.1 0.0 0.0   Shareholders equity total   319 297 285 348 323 351 202 202   Interest-bearing liabilities   70.4 58.1 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   479 425 408 455 442 550 202 202   Net Debt   47.8 41.3 0.0 0.0 -30.4 -25.0 -202 -202     See the entire balance sheet 1.0 Volume  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Net sales   692 757 780 727 682 924 924 924   Net sales growth   -8.7% 9.4% 3.1% -6.8% -6.1% 35.4% 0.0% 0.0%   Gross profit   152 27.8 99.3 182 134 229 0.0 0.0   Gross profit growth   -5.5% -81.7% 256.9% 83.6% -26.7% 71.8% -100.0% 0.0%   Employees   0 174 169 144 142 150 0 0   Employee growth %   0.0% 0.0% -2.9% -14.8% -1.4% 5.6% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   479 425 408 455 442 550 202 202   Balance sheet change%   21.4% -11.3% -4.1% 11.6% -2.8% 24.4% -63.3% 0.0%   Added value   94.1 12.3 99.3 182.2 69.0 163.9 0.0 0.0   Added value %   13.6% 1.6% 12.7% 25.1% 10.1% 17.7% 0.0% 0.0%   Investments   -21 -3 -66 0 39 -4 -49 0   Net sales trend   -1.0 1.0 2.0 -1.0 -2.0 1.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1.0 Profitability  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A EBITDA %   13.6% 1.6% 12.7% 25.1% 11.4% 17.7% 0.0% 0.0%   EBIT %   12.0% 1.2% 12.7% 25.1% 10.1% 17.3% 0.0% 0.0%   EBIT to gross profit (%)   54.5% 33.7% 100.0% 100.0% 51.7% 69.6% 0.0% 0.0%   Net Earnings %   10.1% 4.3% 2.2% 10.7% 7.7% 12.9% 0.0% 0.0%   Profit before depreciation and extraordinary items %   11.7% 4.7% 2.2% 10.7% 9.0% 13.4% 0.0% 0.0%   Pre tax profit less extraordinaries %   12.7% 0.4% 12.7% 25.1% 10.2% 16.7% 0.0% 0.0%   ROA %   22.1% 2.4% 23.8% 42.3% 15.7% 33.0% 0.0% 0.0%   ROI %   27.2% 2.9% 26.4% 42.3% 18.1% 48.5% 0.0% 0.0%   ROE %   22.4% 10.7% 5.8% 24.6% 15.6% 35.5% 0.0% 0.0%   1.0 Solidity  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Equity ratio %   66.6% 70.8% 100.0% 100.0% 79.2% 78.7% 100.0% 100.0%   Relative indebtedness %   22.7% 18.3% 0.0% 0.0% 17.4% 21.5% 0.0% 0.0%   Relative net indebtedness %   19.5% 16.1% 0.0% 0.0% 13.0% 18.8% -21.8% -21.8%   Net int. bear. debt to EBITDA, %   50.8% 336.2% 0.0% 0.0% -39.1% -15.3% 0.0% 0.0%   Gearing %   22.1% 19.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   22.7% 11.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1.0 Liquidity  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Quick Ratio   1.8 2.3 0.0 0.0 3.5 4.1 0.0 0.0   Current Ratio   2.5 2.7 0.0 0.0 3.4 2.5 0.0 0.0   Cash and cash equivalent   22.7 16.9 0.0 0.0 30.4 25.0 0.0 0.0   1.0 Capital use efficiency  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Trade debtors turnover (days)   117.4 96.0 0.0 0.0 29.6 24.6 0.0 0.0   Trade creditors turnover (days)   159.7 117.9 0.0 0.0 124.5 167.5 0.0 0.0   Current assets / Net sales %   57.1% 50.0% 0.0% 0.0% 57.7% 54.3% 21.8% 21.8%   Net working capital   237.9 239.9 0.0 0.0 276.5 302.5 0.0 0.0   Net working capital %   34.4% 31.7% 0.0% 0.0% 40.5% 32.7% 0.0% 0.0%   1.0 Employee efficiency  2017 2017/12 2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023e N/A 2024e N/A Net sales / employee   0 4 5 5 5 6 0 0   Added value / employee   0 0 1 1 0 1 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 1 1 1 1 0 0   EBIT / employee   0 0 1 1 0 1 0 0   Net earnings / employee   0 0 0 1 0 1 0 0